Definition: Given a passage with a context and an answer, construct a question on the basis of the information present in the passage. Construct the question in such a way that (i) it is unambiguous, (ii) it is answerable from the passage, (iii) its answer is unique (iv) it answer uses text phrases from the passage. Avoid creating questions that (i) can't be answered correctly without actually understanding the passage and (ii) uses the same words or phrases given in the passage.
Input: Context: This open-label, prospective, observational study aimed to evaluate treatment response, efficacy therapy and safety to IFN -2b for the essential thrombocythemia (ET) and polycythemia vera (PV) with JAK2V617F positive mutation.', 'A total of 123 ET patients received IFN-2b therapy with JAK2V617F positive or negative mutation; and 136 PV patients with JAK2V617F(+) received IFN-2b or hydroxyurea (HU) therapy according to random number assignment (ages 18-65 years old).', 'ET patients receiving IFN -2b with JAK2V617F(+) had a greater advantage in overall hematologic response (OHR) than JAK2V617F(-) (83.3% versus 61.4%, P<0.01). For PV patients with JAK2V617F(+), IFN had no OHR superiority to HU (70.3% versus 70.8%, P>0.05), but which gained a greater satisfactory molecular response than HU (54.7% versus 19.4%, P<0.01). IFN significantly decreased the phlebotomy rate, which was better than HU for MPDs patients with OHR than HU (3.6% versus 65.7%, P<0.01). Furthermore, ET patients with JAK2V617F(+) demonstrated a definite advantage over JAK2V617F(-) in five-year PFS (75.9% versus 47.6%, P<0.05). For PV patients with JAK2V617F(+), IFN -2b was superior to HU in five-year PFS (66.3% versus 46.7%, P<0.01). Moreover, IFN -2b also contributed to improved vasomotor symptoms in MPDs, and especially significantly decreased the incidence of distal paresthesias (14.1% versus 37.5%) and erythromelalgia (9.4% versus 29.2%) better than HU (P<0.01). Meanwhile, IFN did not observe the severe hematological adverse events in patients with PV or ET.
Answer: The data confirmed that IFN -2b benefited the patients with ET or PV, particularly for JAK2V617F(+) mutation.
Output:
Does interferon -2b gain high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation?